

FIGURE 1A




FIGURE 1B




FIGURE 2

CD33+ AML Cells					Non-AML (CD33-) Cells				
Cell Line	CC-90009 IC50 (M)	CD33AB-Compound I(a)		Mylotarg IC50 (M)	Cell Line	CC-90009 IC50 (M)	CD33AB-Compound I(a)		Mylotarg IC50 (M)
		conjugate IC50 (M)	conjugate IC50 (M)				conjugate IC50 (M)	conjugate IC50 (M)	
MV-4-11	1.20E-08	9.00E-11	9.00E-11	7.00E-11	RS4;11	4.50E-09	>2.00E-08	5.60E-10	Efficacy
ML-2	9.10E-09	9.00E-11	9.00E-11	2.00E-11	CCRF-CEM	8.04E-09	>2.00E-08	8.56E-09	
HL-60	7.84E-09	1.10E-10	9.00E-11	9.00E-11	TALL-1	4.12E-09	>2.00E-08	2.92E-09	
SKNO-1	4.94E-09	1.60E-10	4.00E-11	4.00E-11	NALM-16	9.60E-09	>2.00E-08	8.02E-09	
F-36P	3.69E-09	2.00E-10	>2.00E-08	>2.00E-08	Molt-4	1.13E-08	>2.00E-08	4.30E-10	Highly effective
Kasumi-6	>2.00E-08	3.40E-10	>2.00E-08	>2.00E-08	LC4-1	1.31E-08	>2.00E-08	1.47E-09	
OCI-AML-4	8.26E-09	3.60E-10	1.00E-10	1.00E-10	Reh	1.37E-08	>2.00E-08	5.80E-10	
Molm-13	>2.00E-08	3.60E-10	3.00E-11	3.00E-11	Loucy	4.07E-09	>2.00E-08	3.31E-09	
AML-193	9.59E-09	4.30E-10	>2.00E-08	>2.00E-08	ATN-1	>2.00E-08	>2.00E-08	8.03E-09	Medium
EoL-1	1.18E-08	5.20E-10	3.00E-11	3.00E-11	SUP-T1	>2.00E-08	>2.00E-08	8.61E-09	
HNT-34	1.33E-09	1.01E-09	5.20E-10	5.20E-10	SUP-B15	>2.00E-08	>2.00E-08	1.78E-09	
Kasumi-3	1.16E-09	1.12E-08	>2.00E-08	>2.00E-08	Jurkat, Clone E6-1	>2.00E-08	>2.00E-08	1.02E-08	
OCI-AML-1	6.44E-09	>2.00E-08	9.00E-11	9.00E-11	THP-1	>2.00E-08	>2.00E-08	2.57E-09	Low
KG-1a	1.27E-08	>2.00E-08	>2.00E-08	>2.00E-08	ARH-77	>2.00E-08	>2.00E-08	8.91E-09	
NOMO-1	>2.00E-08	>2.00E-08	>2.00E-08	>2.00E-08	SKM-1	>2.00E-08	>2.00E-08	4.50E-10	
KASUMI-1	>2.00E-08	>2.00E-08	>2.00E-08	>2.00E-08	Kopn-8	>2.00E-08	>2.00E-08	4.10E-10	
OCI-M1	>2.00E-08	>2.00E-08	>2.00E-08	>2.00E-08	CMK-86	8.01E-09	>2.00E-08	>2.00E-08	>2.00E-08
PLB-985	1.72E-08	>2.00E-08	>2.00E-08	>2.00E-08	CMK-11-5	5.74E-09	>2.00E-08	>2.00E-08	
					KU812	1.49E-08	>2.00E-08	>2.00E-08	
					TF-1a	8.15E-09	>2.00E-08	>2.00E-08	
					GDM-1	6.91E-09	>2.00E-08	>2.00E-08	>2.00E-08

FIGURE 3





FIGURE 4



Sample	Gender	Age	Previous Treatments	Mutations
1	Male	31	1 st : Cytarabine, Idarubicin (7+3). Response: CR 2 nd : Cytarabine. Response: PD	IDH2 P140Q SRSF2 P95H
2	Male	83	Decitabine. Response: CR	NRAS Q61H/Q61K/G12D
3	Female	29	1 st : Cytarabine, Idarubicin (7+3). Response: PR 2 nd : Mitoxantrone, Etoposide, Cytarabine. Response: PD	NRAS Q61K KRAS G12V

FIGURE 5




FIGURE 6

MV4-11




FIGURE 7




FIGURE 8





FIGURE 9



MV411 Mouse Plasma: 3 mpk CD33AB-Compound I(a) Conjugate




FIGURE 10A




FIGURE 10B

